Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.
Markus MeyerDaniel LustgartenPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.
Keyphrases
- heart failure
- catheter ablation
- atrial fibrillation
- angiotensin converting enzyme
- left atrial
- oral anticoagulants
- left atrial appendage
- left ventricular
- direct oral anticoagulants
- percutaneous coronary intervention
- angiotensin ii
- high glucose
- stem cells
- cardiac resynchronization therapy
- diabetic rats
- drug induced
- acute heart failure
- venous thromboembolism
- endothelial cells
- type diabetes
- mesenchymal stem cells
- coronary artery disease
- skeletal muscle
- stress induced
- smoking cessation
- metabolic syndrome